MedTrace Logo

Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas

NCT02323659 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-01-13

No results posted yet for this study

Summary

Comparison of methotrexate versus interferon-alfa 2b on efficacy, safety and quality of life in patients with primary cutaneous T-cell lymphomas after failure of topical or phototherapy treatment.

Conditions

  • Lymphoma, T-Cell, Cutaneous
  • Mycosis Fungoides

Interventions

DRUG

Methotrexate

Methotrexate 20mg per dose, administered orally, once every week

DRUG

Interferon Alfa-2b

Interferon Alfa-2b 3 million international units (MIU), administered 3 times per week

Sponsors & Collaborators

  • Polish Lymphoma Research Group

    lead NETWORK

Principal Investigators

  • Małgorzata Sokołowska Wojdyło, MD, PhD · Polish Lymphoma Research Group

  • Ewa Chmielowska, MD, PhD · Polish Lymphoma Research Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-01
Primary Completion
2018-03-31
Completion
2018-03-31

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02323659 on ClinicalTrials.gov